Published in Int J Cancer on January 01, 2000
The pancreas cancer microenvironment. Clin Cancer Res (2012) 4.10
VEGF targets the tumour cell. Nat Rev Cancer (2013) 2.71
Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. Chem Rev (2010) 2.44
Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am J Pathol (2002) 1.70
Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer (2003) 1.61
Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol Cancer (2003) 1.39
scVEGF microbubble ultrasound contrast agents: a novel probe for ultrasound molecular imaging of tumor angiogenesis. Invest Radiol (2010) 1.35
Vascular endothelial growth factor receptor-2 in breast cancer. Biochim Biophys Acta (2010) 1.32
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs (2008) 1.30
Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells. Br J Cancer (2005) 1.22
Expression of transforming growth factor-beta-1 and p27Kip1 in pancreatic adenocarcinomas: relation with cell-cycle-associated proteins and clinicopathologic characteristics. BMC Cancer (2005) 0.99
The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors. Neoplasia (2005) 0.99
Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer. BMC Cancer (2011) 0.98
Angiogenesis and lymphangiogenesis of gastric cancer. J Oncol (2010) 0.95
Vascular endothelial growth factor receptor type 2-targeted contrast-enhanced US of pancreatic cancer neovasculature in a genetically engineered mouse model: potential for earlier detection. Radiology (2014) 0.95
Vascular endothelial growth factor receptor-2-mediated mitogenesis is negatively regulated by vascular endothelial growth factor receptor-1 in tumor epithelial cells. Am J Pathol (2001) 0.91
Endostatin expression in pancreatic tissue is modulated by elastase. Br J Cancer (2005) 0.89
Tumor cell expression of vascular endothelial growth factor receptor 2 is an adverse prognostic factor in patients with squamous cell carcinoma of the lung. PLoS One (2013) 0.88
Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer. Neoplasia (2010) 0.88
Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer. PLoS One (2012) 0.87
Quercetin-4'-O-β-D-glucopyranoside (QODG) inhibits angiogenesis by suppressing VEGFR2-mediated signaling in zebrafish and endothelial cells. PLoS One (2012) 0.86
Small molecule tyrosine kinase inhibitors in pancreatic cancer. Biologics (2008) 0.85
Expression of vascular endothelial growth factors A and C in human pancreatic cancer. World J Gastroenterol (2006) 0.85
Angiogenesis and lymphangiogenesis are downregulated in primary breast cancer. Br J Cancer (2009) 0.84
Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. Oncotarget (2010) 0.84
Targeted therapies for pancreatic cancer. Br Med Bull (2008) 0.84
Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Cancer Sci (2015) 0.83
Imaging-guided delivery of RNAi for anticancer treatment. Adv Drug Deliv Rev (2016) 0.79
Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials. Chin J Cancer Res (2015) 0.78
Investigating the antiproliferative activity of high affinity DNA aptamer on cancer cells. PLoS One (2013) 0.78
Establishment and characterization of new cell lines of anaplastic pancreatic cancer, which is a rare malignancy: OCUP-A1 and OCUP-A2. BMC Cancer (2016) 0.78
Cytokines as Biomarkers of Pancreatic Ductal Adenocarcinoma: A Systematic Review. PLoS One (2016) 0.76
The inhibition of tyrosine kinase receptor signalling in leiomyosarcoma cells using the small molecule kinase inhibitor PTK787/ZK222584 (Vatalanib®). Int J Oncol (2014) 0.76
Effect of shRNA-mediated knockdown of vascular endothelial growth factor on the proliferation of choroid-retinal endothelial cells under hypoxic conditions. Exp Ther Med (2015) 0.75
First Evidence that Sika Deer (Cervus nippon) Velvet Antler Extract Suppresses Migration of Human Prostate Cancer Cells. Korean J Food Sci Anim Resour (2015) 0.75
Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model. Cancer Lett (2016) 0.75
Expression and clinical significance of vascular endothelial growth factor and fms-related tyrosine kinase 1 in colorectal cancer. Oncol Lett (2015) 0.75
Molecular therapeutics in pancreas cancer. World J Gastrointest Oncol (2016) 0.75
Ultrasound Molecular Imaging of Angiogenesis Using Vascular Endothelial Growth Factor-Conjugated Microbubbles. Mol Pharm (2017) 0.75
Structural basis for signal transduction by the Toll/interleukin-1 receptor domains. Nature (2000) 4.36
Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology (1993) 2.86
Structure of the DNA repair and replication endonuclease and exonuclease FEN-1: coupling DNA and PCNA binding to FEN-1 activity. Cell (1998) 2.67
Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene (2009) 2.49
Saccharomyces cerevisiae RNase H(35) functions in RNA primer removal during lagging-strand DNA synthesis, most efficiently in cooperation with Rad27 nuclease. Mol Cell Biol (1999) 2.29
Cloning and characterization of a phosphopantetheinyl transferase from Streptomyces verticillus ATCC15003, the producer of the hybrid peptide-polyketide antitumor drug bleomycin. Chem Biol (2001) 2.25
Intrinsic fluorescence from DNA can be enhanced by metallic particles. Biochem Biophys Res Commun (2001) 2.25
The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest (1998) 2.22
Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science (1988) 2.22
Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res (1993) 2.15
Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res (1993) 2.08
Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum (2008) 2.05
Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum Pathol (1993) 2.05
Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res (1995) 1.89
The highly recombinogenic bz locus lies in an unusually gene-rich region of the maize genome. Proc Natl Acad Sci U S A (2001) 1.88
Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. Int J Cancer (1999) 1.81
Action of secretagogues on a new preparation of functionally intact, isolated pancreatic acini. Am J Physiol (1978) 1.80
Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res (1997) 1.74
A structural change occurs upon binding of syntaxin to SNAP-25. J Biol Chem (1997) 1.72
In vivo induction of massive proliferation, directed migration, and differentiation of neural cells in the adult mammalian brain. Proc Natl Acad Sci U S A (2000) 1.67
Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis. Eur J Immunol (2000) 1.65
The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene (1999) 1.63
Malonyl-coenzyme A:acyl carrier protein acyltransferase of Streptomyces glaucescens: a possible link between fatty acid and polyketide biosynthesis. Biochemistry (1995) 1.60
Microarray-based identification of differentially expressed growth- and metastasis-associated genes in pancreatic cancer. Cell Mol Life Sci (2003) 1.60
KAI1 expression is up-regulated in early pancreatic cancer and decreased in the presence of metastases. Cancer Res (1996) 1.59
Pancreatic islet-acinar cell interaction: amylase messenger RNA levels ar determined by insulin. Science (1981) 1.59
Construction and initial characterization of Escherichia coli strains with few or no intact chromosomal rRNA operons. J Bacteriol (1999) 1.58
Genes for production of the enediyne antitumor antibiotic C-1027 in Streptomyces globisporus are clustered with the cagA gene that encodes the C-1027 apoprotein. Antimicrob Agents Chemother (2000) 1.58
Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res (2001) 1.55
Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Pathol (2001) 1.54
Enhanced expression of the type II transforming growth factor beta receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res (1993) 1.53
The effects of liver transplantation on the clinical course of colitis in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther (2012) 1.52
Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle. Proc Natl Acad Sci U S A (1987) 1.51
Mutational spectrum analysis of RNase H(35) deficient Saccharomyces cerevisiae using fluorescence-based directed termination PCR. Nucleic Acids Res (2000) 1.50
Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer (1997) 1.47
Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut (2001) 1.46
Diagnostic value of clonality of surface immunoglobulin light and heavy chains in malignant lymphoproliferative disorders. Am J Hematol (1993) 1.45
Differential regulation of expression of three transforming growth factor beta species in human breast cancer cell lines by estradiol. Cancer Res (1990) 1.45
The DNA-binding and enhancer-blocking domains of the Drosophila suppressor of Hairy-wing protein. Mol Cell Biol (1996) 1.44
Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer. Pancreas (1999) 1.41
A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling. Proc Natl Acad Sci U S A (1994) 1.41
Identification and characterization of an eight-cysteine repeat of the latent transforming growth factor-beta binding protein-1 that mediates bonding to the latent transforming growth factor-beta1. J Biol Chem (1996) 1.40
Nerve growth factor expression correlates with perineural invasion and pain in human pancreatic cancer. J Clin Oncol (1999) 1.38
Diagnostic value of serum gamma-glutamyl transferase isoenzyme for hepatocellular carcinoma: a 10-year study. Am J Gastroenterol (1992) 1.37
Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer (2000) 1.37
Human exonuclease 1 functionally complements its yeast homologues in DNA recombination, RNA primer removal, and mutation avoidance. J Biol Chem (1999) 1.36
Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology (1999) 1.36
Aberrant expression of type I fibroblast growth factor receptor in human pancreatic adenocarcinomas. Cancer Res (1993) 1.36
Hybrid peptide-polyketide natural products: biosynthesis and prospects toward engineering novel molecules. Metab Eng (2001) 1.35
Nerve growth factor and its high-affinity receptor in chronic pancreatitis. Ann Surg (1999) 1.35
Connective tissue growth factor is a regulator for fibrosis in human chronic pancreatitis. Ann Surg (1999) 1.34
Id-1 and Id-2 are overexpressed in pancreatic cancer and in dysplastic lesions in chronic pancreatitis. Am J Pathol (1999) 1.33
Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer. Proc Natl Acad Sci U S A (1986) 1.33
Induction and expression of amphiregulin in human pancreatic cancer. Cancer Res (1994) 1.32
Interleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions. Br J Cancer (2005) 1.31
Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol (1998) 1.30
Structural biochemistry of a type 2 RNase H: RNA primer recognition and removal during DNA replication. J Mol Biol (2001) 1.30
Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. J Rheumatol (1995) 1.28
Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma. Am J Surg (1999) 1.27
A KrasG12D-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis. Oncogene (2011) 1.27
Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer. Int J Cancer (1995) 1.26
Anomalous photogalvanic effect of circularly polarized light incident on the two-dimensional electron gas in Al{x}Ga{1-x}N/GaN heterostructures at room temperature. Phys Rev Lett (2008) 1.25
Roles for beta(pat-3) integrins in development and function of Caenorhabditis elegans muscles and gonads. J Biol Chem (2001) 1.24
Enhanced expression of the insulin receptor substrate-2 docking protein in human pancreatic cancer. Cancer Res (1998) 1.24
Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer. Cancer Res (1994) 1.23
Stimulation of eukaryotic flap endonuclease-1 activities by proliferating cell nuclear antigen (PCNA) is independent of its in vitro interaction via a consensus PCNA binding region. J Biol Chem (2001) 1.21
Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. Int J Cancer (2001) 1.21
Mutagenesis of structural half-cystine residues in human thioredoxin and effects on the regulation of activity by selenodiglutathione. Biochemistry (1993) 1.20
Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression. Clin Cancer Res (1995) 1.19
Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest (1998) 1.19
Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer. Biochem Biophys Res Commun (1994) 1.18
Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors. J Mol Med (Berl) (1996) 1.18
Increased expression of transforming growth factor beta isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium: evidence for paracrine and autocrine action. Cancer Res (1994) 1.18
Blockage of intermediate-conductance-Ca(2+) -activated K(+) channels inhibits progression of human endometrial cancer. Oncogene (2007) 1.17
Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation. Clin Cancer Res (2001) 1.16
Transforming growth factor beta mediates the progesterone suppression of an epithelial metalloproteinase by adjacent stroma in the human endometrium. Proc Natl Acad Sci U S A (1995) 1.13
Increased expression of keratinocyte growth factor in human pancreatic cancer. Biochem Biophys Res Commun (1995) 1.13
Expression of hsp90 and cyclin D1 in human breast cancer. Cancer Lett (1999) 1.13
bax, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut (1998) 1.12
Biosynthesis of hybrid peptide-polyketide natural products. Curr Opin Drug Discov Devel (2001) 1.12
Increased expression of insulin receptor substrate-1 in human pancreatic cancer. Biochem Biophys Res Commun (1996) 1.12
Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells. Int J Cancer (2000) 1.12
Synthesis and expression of transforming growth factor beta-1, beta-2, and beta-3 in the endocrine and exocrine pancreas. Diabetes (1993) 1.12
The mouse ocular albinism 1 gene product is an endolysosomal protein. Exp Eye Res (2001) 1.11
Human RAD2 homolog 1 5'- to 3'-exo/endonuclease can efficiently excise a displaced DNA fragment containing a 5'-terminal abasic lesion by endonuclease activity. J Biol Chem (1996) 1.11
Cytosolic calcium regulates epidermal growth factor endocytosis in rat pancreas and cultured fibroblasts. Proc Natl Acad Sci U S A (1984) 1.10
Enhanced urokinase plasminogen activation in chronic pancreatitis suggests a role in its pathogenesis. Gastroenterology (1997) 1.09
Cell cycle-dependent and DNA damage-inducible nuclear localization of FEN-1 nuclease is consistent with its dual functions in DNA replication and repair. J Biol Chem (2000) 1.09
p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett (1993) 1.09
Identification and characterization of a type II peptidyl carrier protein from the bleomycin producer Streptomyces verticillus ATCC 15003. Chem Biol (1999) 1.09
Stable transfection of a glypican-1 antisense construct decreases tumorigenicity in PANC-1 pancreatic carcinoma cells. Pancreas (1999) 1.08
Neurotensin receptor-1 mRNA analysis in normal pancreas and pancreatic disease. Clin Cancer Res (2000) 1.08